LSV Asset Management Invests $807,000 in SIGA Technologies, Inc. (NASDAQ:SIGA)

LSV Asset Management purchased a new position in SIGA Technologies, Inc. (NASDAQ:SIGA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 106,388 shares of the company’s stock, valued at approximately $807,000.

A number of other institutional investors have also recently made changes to their positions in SIGA. Steward Partners Investment Solutions LLC bought a new position in shares of SIGA Technologies during the 4th quarter valued at $58,000. Bayesian Capital Management LP bought a new position in shares of SIGA Technologies during the 1st quarter valued at $97,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of SIGA Technologies by 38.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock valued at $104,000 after purchasing an additional 3,829 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of SIGA Technologies during the 1st quarter valued at $105,000. Finally, EntryPoint Capital LLC bought a new position in shares of SIGA Technologies during the 1st quarter valued at $111,000. Institutional investors own 55.40% of the company’s stock.

SIGA Technologies Stock Performance

SIGA stock opened at $7.87 on Friday. SIGA Technologies, Inc. has a 52 week low of $4.26 and a 52 week high of $12.83. The firm’s fifty day moving average is $9.04 and its 200 day moving average is $8.17. The firm has a market cap of $561.68 million, a P/E ratio of 7.15 and a beta of 0.91.

SIGA Technologies (NASDAQ:SIGA) last released its earnings results on Thursday, August 1st. The company reported $0.03 EPS for the quarter. The company had revenue of $21.81 million for the quarter. SIGA Technologies had a net margin of 48.55% and a return on equity of 51.40%. During the same period in the prior year, the business posted ($0.04) EPS. As a group, analysts forecast that SIGA Technologies, Inc. will post 1.01 EPS for the current year.

SIGA Technologies Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.